Skip to main content
. 2017 Aug 3;102(10):1629–1639. doi: 10.3324/haematol.2017.164103

Figure 6.

Figure 6

Recommendations for the clinic summarizing important toxicity-related issues during therapy with ibrutinib or idelalisib. DOAC: directly acting oral anticoagulants; LMWH: low-molecular-weight heparin; PJP: Pneumocystis jiroveci pneumonia; CMV: cytomegalovirus.